Docsity
Log inSign up
Docsity
Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity

Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan

Guidelines and tips
Guidelines and tips
Sell on Docsity
Sell on Docsity
Log inSign up

Prepare for your exams

Study with the several resources on Docsity

Find documents

Prepare for your exams with the study notes shared by other students like you on Docsity

Search Store documents

The best documents sold by students who completed their studies

Search through all study resources
Docsity AINEW

Summarize your documents, ask them questions, convert them into quizzes and concept maps

Explore questions

Clear up your doubts by reading the answers to questions asked by your fellow students

Earn points to download

Earn points by helping other students or get them with a premium plan

Share documents
download point icon20 Points

For each uploaded document

Answer questions
download point icon5 Points

For each given answer (max 1 per day)

All the ways to get free points
Get points immediately

Choose a premium plan with all the points you need

Study Opportunities

Choose your next study program

Get in touch with the best universities in the world. Search through thousands of universities and official partners

Community

Ask the community

Ask the community for help and clear up your study doubts

University Rankings

Discover the best universities in your country according to Docsity users

Free resources

Our save-the-student-ebooks!

Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors

From our blog

Exams and Study
Go to the blog

Pharmacotherapeutics For Advanced Practice Nurse Prescribers: Chapter 6. An Introductio, Exams of Nursing

Rhodes State CollegeNursing

Pharmacotherapeutics For Advanced Practice Nurse Prescribers: Chapter 6. An Introduction To Pharmacogenomics Exam Questions With Verified Answers

Typology: Exams

2024/2025

Available from 05/29/2025

drillmaster
drillmaster 🇺🇸

5

(5)

839 documents

1 / 5

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
Pharmacotherapeutics For Advanced
Practice Nurse Prescribers: Chapter 6.
An Introduction To Pharmacogenomics
Exam Questions With Verified Answers
UPGRADED A+
Genetic polymorphisms account for differences in metabolism, including:
1. Poor metabolizers, who lack a working enzyme
2. Intermediate metabolizers, who have one working, wild-type allele and one mutant allele
3. Extensive metabolizers, with two normally functioning alleles
4. All of the above
ANS: 4
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
1. A need to monitor drugs metabolized by 2D6 for toxicity
2. Increased dosages needed of drugs metabolized by 2D6, such as the selective serotonin reuptake
inhibitors
3. Decreased conversion of codeine to morphine by CYP2D6
4. The need for lowered dosages of drugs, such as beta blockers
ANS: 2
pf3
pf4
pf5

Partial preview of the text

Download Pharmacotherapeutics For Advanced Practice Nurse Prescribers: Chapter 6. An Introductio and more Exams Nursing in PDF only on Docsity!

Pharmacotherapeutics For Advanced

Practice Nurse Prescribers: Chapter 6.

An Introduction To Pharmacogenomics

Exam Questions With Verified Answers

UPGRADED A+

Genetic polymorphisms account for differences in metabolism, including:

  1. Poor metabolizers, who lack a working enzyme
  2. Intermediate metabolizers, who have one working, wild-type allele and one mutant allele
  3. Extensive metabolizers, with two normally functioning alleles
  4. All of the above

ANS: 4

Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:

  1. A need to monitor drugs metabolized by 2D6 for toxicity
  2. Increased dosages needed of drugs metabolized by 2D6, such as the selective serotonin reuptake inhibitors
  3. Decreased conversion of codeine to morphine by CYP2D
  4. The need for lowered dosages of drugs, such as beta blockers

ANS: 2

Rifampin is a nonspecific CYP450 inducer that may:

  1. Lead to toxic levels of rifampin and so must be monitored closely
  2. Cause toxic levels of drugs, such as oral contraceptives, when coadministered
  3. Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic failure
  4. Cause nonspecific changes in drug metabolism

ANS: 3

Inhibition of P-glycoprotein by a drug such as quinidine may lead to:

  1. Decreased therapeutic levels of quinidine
  2. Increased therapeutic levels of quinidine
  3. Decreased levels of a coadministered drug, such as digoxin, that requires P-glycoprotein for absorption and elimination
  4. Increased levels of a coadministered drug, such as digoxin, that requires P-glycoprotein for absorption and elimination

ANS: 4

Warfarin resistance may be seen in patients with a VKORC1 mutation, leading to:

  1. Toxic levels of warfarin building up
  2. Decreased response to warfarin
  3. Increased risk for significant drug interactions with warfarin
  1. Increased risk for Stevens-Johnson syndrome in Asian patients with the HLA-B*1502 allele
  2. Patients who have the HLA-B*1502 allele being more likely to have a resistance to carbamazepine

ANS: 3

A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to:

  1. Decreased effectiveness of irinotecan in the treatment of cancer
  2. Increased adverse drug reactions, such as neutropenia
  3. Delayed metabolism of the prodrug irinotecan into the active metabolite SN- 38
  4. Increased concerns for irinotecan being carcinogenic

ANS: 2

Patients who have a poor metabolism phenotype will have:

  1. Slowed metabolism of a prodrug into an active drug, leading to accumulation of prodrug
  2. Accumulation of inactive metabolites of drugs
  3. A need for increased dosages of medications
  4. Increased elimination of an active drug

ANS: 1

Ultra-rapid metabolizers of drugs may have:

  1. To have dosages of drugs adjusted downward to prevent drug accumulation
  2. Active drug rapidly metabolized into inactive metabolites, leading to potential therapeutic failure
  3. Increased elimination of active, nonmetabolized drug
  4. Slowed metabolism of a prodrug into an active drug, leading to an accumulation of prodrug

ANS: 2

A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast cancer to:

  1. Ensure the patient will not have increased adverse drug reactions to the tamoxifen
  2. Identify potential drug-drug interactions that may occur with tamoxifen
  3. Reduce the likelihood of therapeutic failure with tamoxifen treatment
  4. Identify poor metabolizers of tamoxifen

ANS: 3